KISSEI PHARMACEUTICAL CO.,LTD. Logo

KISSEI PHARMACEUTICAL CO.,LTD.

Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.

4547 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
松本市芳野19番48号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kissei Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company engaged in the development, manufacturing, and commercialization of innovative medicines. The company strategically focuses its research and development efforts on specific therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its business model integrates in-house drug discovery with strategic partnerships, such as in-licensing and out-licensing agreements, to build a robust product pipeline. Kissei's portfolio comprises both specialty and generic drugs, aiming to address unmet medical needs and contribute to the health of people globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-27 06:00
Regulatory News Service
臨時報告書
Japanese 23.3 KB
2025-06-24 06:01
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 06:01
Governance Information
内部統制報告書-第80期(2024/04/01-2025/03/31)
Japanese 25.5 KB
2025-06-24 06:00
Annual Report
有価証券報告書-第80期(2024/04/01-2025/03/31)
Japanese 1.5 MB
2025-06-11 06:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2024-12-27 08:00
Major Shareholding Notification
大量保有報告書
Japanese 38.5 KB
2024-12-13 05:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-11-13 05:01
Interim Report
確認書
Japanese 9.0 KB
2024-11-13 05:00
Interim Report
半期報告書-第80期(2024/04/01-2025/03/31)
Japanese 240.5 KB
2024-06-28 06:00
Post-Annual General Meeting Information
臨時報告書
Japanese 29.4 KB
2024-06-25 06:01
Governance Information
内部統制報告書-第79期(2023/04/01-2024/03/31)
Japanese 23.8 KB
2024-06-25 06:00
Registration Form
確認書
Japanese 9.0 KB
2024-06-25 06:00
Registration Form
有価証券報告書-第79期(2023/04/01-2024/03/31)
Japanese 1.5 MB
2024-02-13 05:00
Quarterly Report
確認書
Japanese 9.0 KB
2024-02-13 05:00
Quarterly Report
四半期報告書-第79期第3四半期(2023/10/01-2023/12/31)
Japanese 193.7 KB

Automate Your Workflow. Get a real-time feed of all KISSEI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for KISSEI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.